CD274 and neoplasm: Immune checkpoint inhibitors (ICIs) promote antitumor immunity by preventing inhibitory signaling through checkpoint receptors such as programmed death‐1 (PD‐1) and cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4) expressed on T lymphocytes and their ligands programmed death ligand‐1 (PD‐L1) and CD80/CD86, respectively, expressed on tumor cells and other immune cells.1, 2